Publications
-
Publication Reference Year Symeres Authors Customer Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18 F]Canagliflozin in Patients with Type 2 Diabetes Clin. Pharmacol. Ther. 2023 Mar 10 2023 UMCG Ton Visser, Andre Heeres UMCG -
Publication Reference Year Symeres Authors Customer Rapid deracemization through solvent cycling: proof-of-concept using a racemizable conglomerate clopidogrel precursor Chem. Commun., 2023,59, 3838-3841 2023 Michel Leeman, Richard Kellog AMOLF institute -
Publication Reference Year Symeres Authors Customer Amino Acid-Metabolizing Enzymes in Advanced High-Grade Serous Ovarian Cancer Patients: Value of Ascites as Biomarker Source and Role for IL4I1 and IDO1 (Oncolines publication) Cancers 2023, 15(3), 893 2023 (Oncolines) Yvonne Grobben, Guido Zaman Radboud University Medical Center and Pangaea Oncology -
Publication Reference Year Symeres Authors Customer Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model compounds J Pharmaceut Biomed 225 (2023) 115219 2023 Juha Jyrkäs, Ari Tolonen University of Oulu -
Publication Reference Year Symeres Authors Customer π-Facial selectivity in the Diels–Alder reaction of glucosamine-based chiral furans and maleimides Org. Biomol. Chem., 2023, Advance Article 2023 Kees van der Loo, Mark Borst, Kees Pouwer University of Groningen, Department of Chemical Biology, Stratingh Institute for Chemistry -
Publication Reference Year Symeres Authors Customer Discovery of oxazoline enhancers of cellular progranulin release Bioorg. Med. Chem. Lett. 80 (2023), 129048 2023 Steven Hoekman, Ondrej Longin, Henk Regeling, Wim Zonneveld, Roel Bell Arkuda Therapeutics -
Publication Reference Year Symeres Authors Customer Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020 (Oncolines publication) Front. Oncol., Sec. Cancer Molecular Targets and Therapeutics 12 – 2022 2022 (Oncolines) Jeffrey Kooijman, Helma Simons-van Riel, Jelle Dylus, Yvonne Grobben, Tessa de Bitter, Antoon van Doornmalen, Janneke Melis, Jeroen de Roos, Nicole Willemsen-Seegers, Guido Zaman NTRC -
Publication Reference Year Symeres Authors Customer The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models Cancer Research Communications (2022) 2 (4): 233–245. 2022 Ruben Leenders, Anita Wegert Oslo University -
Publication Reference Year Symeres Authors Customer TMTHSI, a superior 7-membered ring alkyne containing reagent for strain-promoted azide–alkyne cycloaddition reactions Chemical Science 2022, 33 2022 Harald Veldhuis, Tommi Meulemans Cristal Therapeutics -
Publication Reference Year Symeres Authors Customer Chiral Amplification through the Interplay of Racemizing Conditions and Asymmetric Crystal Growth J. Am. Chem. Soc. 2023, 145, 1, 436-442 2022 Michel Leeman, Richard Kellog Amolf instituut and Innosyn
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
